Several months after an FDA advisory committee delivered an overwhelmingly positive vote (20-2) in favor of approving Vivus’ Qnexa for the treatment of obesity, the...

In previous issues, we’ve documented the arduous journey of Orexigen’s anti-obesity drug Contrave through the regulatory process. In December, an FDA Advisory Committee...

On May 14, HBO premiered its four-part documentary series on obesity, The Weight of the Nation . Each part – entitled “Consequences,” “Choices,” “Children in Crisis,”...

Novo Nordisk’s Head of China Ron Christie divulges details on the state of diabetes care in the world’s most populous nation.

The Obesity Society's annual meeting has long been our favorite place to catch up on the basic science research behind this critical problem.

If you’ve been following our coverage of Orexigen’s obesity drug, Contrave, you’re likely aware that it has been through a regulatory rollercoaster over the past few...

Over the past several years, the use of GLP-1 drugs (such as Byetta and Victoza) together with basal insulins (such as Lantus and Levemir) as a treatment for type 2...

Recently, increasing evidence has suggested that weight-loss surgery (called “bariatric surgery”) can help improve type 2 diabetes management (or even cause its reversal...

In late November, the Centers for Medicare and Medicaid Services (the federal agency that administers the two public insurance programs) announced that Medicare would...

As we have previously written, Vivus’ weight loss drug Qnexa is up for approval in the US in April of this year. Encouragingly, Vivus announced recently that, if...

In late March, the International Diabetes Federation (IDF) released a "position statement" recommending the consideration of bariatric surgery to treat type 2 diabetes...

diaTribe 's take on the recent New England Journal of Medicine's piece on weight gain - and loss!

Kelly on the shocking new data just released on diabetes costs and what we can do about it.

During the US Open tennis tournament earlier this month, Larry Soler of the Partnership for a Healthier America (PHA) announced a pair of new initiatives to promote...

James Hirsch assesses the implications for diabetes from the bestseller Salt Sugar Fat .

Retrofit CEO Jeff Hyman explains what makes data-driven weight loss – using Skype sessions and Wifi scales– so different.

The 30th Annual Obesity Society Meeting brings exciting insights on drugs and mobile health.

The past few months have seen the approval of a pair of new drugs designed to treat obesity, Arena’s Belviq (see new now next in diaTribe #44) and Vivus’ Qsymia (see new...

In late November, Vivus launched its Get Started! Program , which gives potential users of its weight management medication Qsymia a chance to try the drug free for two...

On June 27, the FDA approved Arena Pharmaceutical’s weight-loss drug Belviq (lorcaserin), the first weight-loss drug to be approved in the US in 13 years. Belviq is...